Floatz logo

Romidepsin

Acute Myeloid Leukemia

Sawa Ito, MDSmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
59/ 100

Competitive context

373 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Idarubicine
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Daunorubicin
Shen yang
Phase 4BB
ETOPOSIDE
Memorial Sloan Kettering Cancer Center
Phase 4BB
CYCLOSPORIN A
City of Hope Medical Center
Phase 4BB
Decitabine
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →